Letters
Reply: Insufficient Evidence for Interaction Between Haptoglobin Phenotypes and Intensive Glycemic Control on Cardiovascular Outcomes

https://doi.org/10.1016/j.jacc.2020.04.035Get rights and content
Under an Elsevier user license
open archive

Cited by (0)

Please note: This study was funded by a Dalhousie University Department of Medicine Ad Hoc Operating Grant and a Nova Scotia Health Authority Research Fund grant to Dr. Cahill. Additional funding was received in part from the Israel Science Foundation (grant 190/16) to Dr. Levy. The original ACCORD study was funded by the U.S. National Institutes of Health. The funding sources were not involved in data collection, data analysis, or manuscript drafting. Dr. Levy is the author of a patent owned by his university regarding use of haptoglobin genotype to predict susceptibility to cardiovascular disease in individuals with diabetes. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. P.K. Shah, MD, served as Guest Associate Editor and Guest Editor-in-Chief for this paper.

The authors attest they are in compliance with human studies committees and animal welfare regulations of the authors’ institutions and Food and Drug Administration guidelines, including patient consent where appropriate. For more information, visit the JACC author instructions page.